Bikanta’s Board of Advisors is being led by Professor Peter Dobson, Principal Fellow at University of Warwick’s Manufacturing Group. As Director of Oxford’s Begbroke Science Park from 2002-2013, he was involved in the initial stages of many (>25) start-up companies. He has himself spun-off multiple companies including Oxonica, Oxford Biosensors, and Oxford NanoSystems, published over 180 papers and 30 patents, and been the Strategic Advisor on Nanotechnology to the UK Research Councils.

Harvard MBA and finance executive Ileane Rosenthal, has been the Co-Founder of the International Biomedical Research Alliance, President of Churchill Partners, and Executive Vice President of Securities Industry and Financial Markets Association (SIMFA). She brings strengths in strategic business development, client relationship management, marketing, funding, and program growth to Bikanta’s Board of Advisors.

Five time CEO and currently that of Oncocyte, William Annett’s expansive diagnostics industry experience includes CEO at BioFX Laboratories (sold to a large life sciences company), founding and leading prenatal diagnostics Corra Life Sciences, and significant management positions at Genentech and Accenture. At Genentech, he led large operational projects with a $150 million budget and >400 team members and supported all development pipeline products and >200 clinical trials. As Managing Director at Accenture, he founded, built, and headed West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory.

A 25 year veteran in biotech, Dr. Nalini Murdter has worked in the early stages to establish global businesses across life sciences and diagnostics markets. Currently Managing Director at JSR Micro, her previous roles have included Chief Business Officer at San Diego Blood Bank and NanoString Technologies and senior management positions at Agilent Technologies and Adeza Biomedical in Marketing, Acquisitions, Alliances, Venture, and Business Development. She is on the Board of Directors of the National Lymphedema Network, was previously an American Cancer Society Fellow, and a Senior Research Fellow at California Institute of Technology.

Professor Dean Ho currently holds a position in the Division of Oral Biology and Medicine and Division of Advanced Prosthodontics, Biomaterials, and Hospital Dentistry while also being the Co-Director of the Center for Reconstructive Biotechnology at UCLA. Highly recognized with many awards and high impact publications, Dr. Ho’s research has been in nanomedicine and on the development of nanodiamond complexes for clinically translatable applications, particularly for cancer therapy and wound healing. He was previously an Associate Professor Northwestern University.